PL3280417T3 - Podstawione ksantyną karbaminiany alkinylu/odwrócone karbaminiany jako antagoniści A<sub>2B</sub> - Google Patents

Podstawione ksantyną karbaminiany alkinylu/odwrócone karbaminiany jako antagoniści A<sub>2B</sub>

Info

Publication number
PL3280417T3
PL3280417T3 PL16777436T PL16777436T PL3280417T3 PL 3280417 T3 PL3280417 T3 PL 3280417T3 PL 16777436 T PL16777436 T PL 16777436T PL 16777436 T PL16777436 T PL 16777436T PL 3280417 T3 PL3280417 T3 PL 3280417T3
Authority
PL
Poland
Prior art keywords
carbamates
xanthine
antagonists
reverse
substituted alkynyl
Prior art date
Application number
PL16777436T
Other languages
English (en)
Inventor
Robert Thompson
Anthony Beauglehole
Guoquan Wang
Original Assignee
Lewis And Clark Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lewis And Clark Pharmaceuticals, Inc. filed Critical Lewis And Clark Pharmaceuticals, Inc.
Publication of PL3280417T3 publication Critical patent/PL3280417T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL16777436T 2015-04-08 2016-04-08 Podstawione ksantyną karbaminiany alkinylu/odwrócone karbaminiany jako antagoniści A<sub>2B</sub> PL3280417T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144371P 2015-04-08 2015-04-08
PCT/US2016/026807 WO2016164838A1 (en) 2015-04-08 2016-04-08 Xanthine-substituted alkynyl carbamates/reverse carbamates as a2b antagonists
EP16777436.3A EP3280417B1 (en) 2015-04-08 2016-04-08 Xanthine-substituted alkynyl carbamates/reverse carbamates as a2b antagonists

Publications (1)

Publication Number Publication Date
PL3280417T3 true PL3280417T3 (pl) 2020-12-28

Family

ID=57072855

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16777436T PL3280417T3 (pl) 2015-04-08 2016-04-08 Podstawione ksantyną karbaminiany alkinylu/odwrócone karbaminiany jako antagoniści A<sub>2B</sub>

Country Status (16)

Country Link
US (1) US9593118B2 (pl)
EP (1) EP3280417B1 (pl)
JP (1) JP6738405B2 (pl)
KR (1) KR20170133493A (pl)
CN (1) CN107530349B (pl)
AU (1) AU2016246068B2 (pl)
BR (1) BR112017021386A2 (pl)
DK (1) DK3280417T3 (pl)
EA (1) EA036954B1 (pl)
ES (1) ES2828574T3 (pl)
IL (1) IL254902B (pl)
MX (1) MX380672B (pl)
PL (1) PL3280417T3 (pl)
PT (1) PT3280417T (pl)
SG (1) SG11201707753XA (pl)
WO (1) WO2016164838A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3090922A1 (en) * 2018-02-16 2019-08-22 Arcus Biosciences, Inc. Dosing with an azolopyrimidine compound
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.
CN112028891B (zh) * 2019-07-30 2022-07-05 厦门宝太生物科技股份有限公司 腺苷受体拮抗剂
CN112592354B (zh) 2019-07-30 2022-05-27 厦门宝太生物科技股份有限公司 一种异噁唑并嘧啶类杂环化合物的制备方法
US20230144283A1 (en) * 2020-03-26 2023-05-11 Inspyr Therapeutics,Inc. 8-substituted diaryl xanthines as dual a2a-a2b antagonists
WO2022050230A1 (ja) * 2020-09-03 2022-03-10 学校法人埼玉医科大学 アデノシン受容体の活性化を抑制する組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558051A (en) 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
US6187780B1 (en) 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
US7253176B1 (en) 2000-05-04 2007-08-07 K.U. Leuven Research & Development Immunosuppressive effects of 8-substituted xanthine derivatives
WO2006091896A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyridyl substituted xanthines
EP1939197A1 (en) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
KR20090094465A (ko) * 2006-12-22 2009-09-07 슈바르츠 파르마 악티엔게젤샤프트 선택적 ａ2ａ 수용체 안타고니스토로서의 8-알키닐잔틴 유도체
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
WO2011005871A1 (en) * 2009-07-07 2011-01-13 Pgxhealth, Llc Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists
CN107082782B (zh) * 2013-03-15 2020-03-20 海德拉生物科学有限责任公司 取代的黄嘌呤及其使用方法

Also Published As

Publication number Publication date
KR20170133493A (ko) 2017-12-05
CN107530349A (zh) 2018-01-02
DK3280417T3 (da) 2020-11-02
EP3280417A1 (en) 2018-02-14
EP3280417B1 (en) 2020-07-29
US20160297819A1 (en) 2016-10-13
US9593118B2 (en) 2017-03-14
EA201792156A1 (ru) 2018-09-28
MX380672B (es) 2025-03-12
ES2828574T3 (es) 2021-05-26
EP3280417A4 (en) 2019-01-23
MX2017012783A (es) 2018-01-30
BR112017021386A2 (pt) 2018-07-03
PT3280417T (pt) 2020-10-30
EA036954B1 (ru) 2021-01-19
SG11201707753XA (en) 2017-10-30
JP6738405B2 (ja) 2020-08-12
IL254902A0 (en) 2017-12-31
JP2018510918A (ja) 2018-04-19
CN107530349B (zh) 2021-01-08
AU2016246068A1 (en) 2017-11-16
WO2016164838A1 (en) 2016-10-13
AU2016246068B2 (en) 2020-08-27
IL254902B (en) 2021-05-31

Similar Documents

Publication Publication Date Title
GB201508727D0 (en) Polyurethane
PL3221519T3 (pl) Układ rusztowaniowy
PL3364945T3 (pl) Stały preparat
IL254902B (en) Alkynyl carbamates/xanthine-substituted inverse carbamates as a2b antagonists
GB201514758D0 (en) Formulation
GB201511225D0 (en) Novel structure
PL3245344T3 (pl) Konstrukcja słupowo-ryglowa
GB201522309D0 (en) Use
GB201522311D0 (en) Use
ES2873376T5 (en) Maropitant formulation
PL3137703T3 (pl) Konstrukcja elewacji
GB201618111D0 (en) Roof Arrangement
PL3257657T3 (pl) Struktura zapobiegająca wyciekaniu
GB201521085D0 (en) Use
GB201521771D0 (en) Formulation
GB201523035D0 (en) In terferometry
GB201518466D0 (en) Use
GB201511255D0 (en) Formulation
GB201509891D0 (en) Formulation
GB201510077D0 (en) Use
GB201502393D0 (en) Senescence
AU365028S (en) Awning
GB201515248D0 (en) Polytunnel structure
IL242773A0 (en) Assembly kit
GB201522443D0 (en) Use